

1 **Signal-independent activation reveals two-component regulatory networks.**

2

3 Cosme CLAVERIE ¹ [#], Francesco COPPOLINO ^{1,2} [#], Maria-Vittoria MAZZUOLI ¹, Cécile
4 GUYONNET ^{3,4,5}, Elise JACQUEMET ⁶, Rachel LEGENDRE ⁶, Odile SISMEIRO ¹, Giuseppe
5 Valerio DE GAETANO ², Giuseppe TETI ⁷, Patrick TRIEU-CUOT ¹, Asmaa TAZI ^{3,4,5},
6 Concetta BENINATI ², Arnaud FIRON ¹ ^{*}

7

8 ¹ Institut Pasteur, Université Paris Cité, Department of Microbiology, Biology of Gram-Positive
9 Pathogens, Paris, France

10 ² University of Messina, Department of Human Pathology, Messina, Italy

11 ³ Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Department of Bacteriology, French
12 National Reference Center for Streptococci, Paris, France

13 ⁴ Université Paris Cité, Institut Cochin, Institut National de la Santé et de la Recherche Médicale
14 U1016, Centre National de la Recherche Scientifique UMR8104, Team Bacteria and
15 Perinatology, Paris, France

16 ⁵ Fédération Hospitalo-Universitaire Fighting Prematurity, Paris, France

17 ⁶ Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Paris, France

18 ⁷ Scylla Biotech Srl, Messina, Italy

19

20 # These authors contributed equally

21 * Correspondence to Arnaud Firon: arnaud.firon@pasteur.fr, tel: +33 (0)140613676

22

23 **ABSTRACT**

24 Each bacterial species has specific regulatory systems to control physiology, adaptation, and
25 host interactions. One challenge posed by this diversity is to define the evolving gene regulatory
26 networks. This study aims to characterise two-component systems (TCS) in *Streptococcus*
27 *agalactiae*, the main cause of neonatal meningitis. Here we demonstrate signal-independent
28 activation of signalling pathways by systematically targeting the conserved mechanism of
29 phosphatase activity of the 14 histidine kinases of the two main TCS families. Transcriptomic
30 analysis resolves most pathways with high resolution, encompassing specialized, connected,
31 and global regulatory systems. The activated network notably reveals the connection between
32 CovRS and SaeRS signaling through the adhesin PbsP, linking the main regulators of host
33 interactions to balance pathogenicity. Additionally, constitutive activation of the BceRS system
34 reveals its role in cell envelope homeostasis beyond antimicrobial resistance. Overall, this study
35 demonstrates the generalizability and versatility of TCS genetic activation to uncover
36 regulatory logics and biological processes.

37

38 **INTRODUCTION**

39 Two-component systems (TCSs) are one of the main bacterial signaling mechanisms. In their
40 simplest form, an environmental signal activates a histidine kinase (HK), which phosphorylates
41 a cognate response regulator (RR), leading to the transcription of specific genes that mediate
42 the cellular response to the stimuli ¹. Actually, TCSs are sophisticated molecular machineries
43 with buffering and insulating mechanisms that dynamically control specific or global cellular
44 responses ²⁻⁴. Considerable effort has been made to define TCS regulatory networks in both
45 model and pathogenic species, including by comprehensive analysis ^{5,6}. Although knowledge
46 gained in one species can provide information about homologous systems, TCS are
47 characterized by their diversity, plasticity and evolvability ^{7,8}. This prevents global inferences
48 even between closely related species ^{9,10}. This evolution of regulatory networks is sustained by
49 several mechanisms, including mutations, horizontal gene transfer, duplication followed by
50 neofunctionalization, and rewiring that shapes adaptation and speciation ¹¹⁻¹³.

51 Functional, evolutionary, and system analyses require characterizing individual
52 signaling pathways and integrating them into the cellular regulatory network. Traditionally,
53 regulons are characterized using inactivated TCS mutants. One common pitfall is that TCSs are
54 not active until the specific, but usually unknown, stimulus is provided. Current approaches to
55 overcome signal requirement are based on phosphomimetic mutation of the RR ^{14,15} and
56 profiling of protein-DNA interaction ¹⁶⁻¹⁸. An alternative approach exploits the distinct HK
57 enzymatic activities. The HK cytoplasmic core, called the transmitter module, is composed of
58 the DHp (Dimerization and Histidine phosphotransfer) and CA (catalytic and ATP-binding)
59 domains ¹⁹⁻²¹. The two domains are dynamically structured in specific conformations that
60 catalyse three distinct reactions: autophosphorylation of a conserved histidine residue in the
61 DHp domain, phosphotransfer to a conserved aspartate on the RR, and RR dephosphorylation.

62 Pioneering studies have identified mutations abolishing the HK phosphatase activity leading to
63 increased RR phosphorylation and signaling pathway activation²²⁻²⁴.

64 The importance of HK phosphatase activity *in vivo* has been initially debated, especially
65 when considering the lability of RR phosphorylation and spontaneous dephosphorylation rate
66²⁵. Nowadays, the phosphatase activity is recognized as essential for the dynamics of the
67 response and to ensure that the RR is activated by the cognate HK only^{26,27}. Co-evolving
68 residues and HKs conformational rearrangements ensure specificity and directionality of
69 enzymatic reactions²⁸⁻³⁰. While the activation mechanism involving the conserved histidine
70 residue is fundamentally conserved among HKs, the phosphatase mechanism has remained
71 more elusive due to variations in the DHp domain³¹. Then, a seminal study has proposed a
72 conserved phosphatase mechanism for the two main HisKA and HisKA_3 family, identifying
73 conserved motifs and specific catalytic residues needed for the correct positioning of
74 nucleophilic attack^{31,32}. Substitution of the catalytic residues abolishes the phosphatase activity
75 without impacting the autokinase and phosphotransfer activities, resulting in increased RR
76 phosphorylation and pathway activation for the individual HKs reported to date³²⁻³⁷.

77 This study aims to systematically test the proposed conserved mechanism of
78 phosphatase activity, the *in vivo* effect of phosphatase-deficient HK, and the activation of the
79 regulatory network in all HisKA and HisKA_3 systems in a bacterium. We focused on
80 *Streptococcus agalactiae* (Group B *Streptococcus*, GBS), a pathobiont that is commensal in
81 adults but pathogenic during pregnancy and in neonates, for whom it is the leading cause of
82 invasive infections^{38,39}. We report that targeting HK phosphatase activity provides high-
83 resolution views of signaling pathways for most TCSs independently from environmental
84 signals. In addition, regulatory network activation resolves the connectivity between TCSs
85 involved in host-pathogen interactions and reveals the physiological function of a TCS involved

86 in antimicrobial resistance. This systematic analysis argues for the widespread adoption of this
87 gain-of-function approach to decipher TCSs signaling in genetically manipulable species.

88

89 **RESULTS**

90 **The HK⁺ collection targets the phosphatase activity of Histidine Kinase.**

91 We undertook a genetic approach to systematically test the hypothesis of a conserved
92 dephosphorylation mechanism in the two major HK families ³². The genome of the BM110
93 strain belonging to the hypervirulent clonal complex 17 (CC-17) encodes 20 HKs ⁴⁰, among
94 which 12 and 2 have a HisKA and HisKA_3 DHp domain, respectively ([Supplementary Table](#)
95 [1](#)). Their H-box motif always contains the conserved phospho-acceptor histidine, immediately
96 followed by the predicted phosphatase motif ([Fig. 1A](#)). Eleven of the twelve HisKA proteins
97 have the E/DxxT/N motif with a putative threonine catalytic residue, while the remaining
98 HisKA protein (BceS) has a divergent sequence composition (QMKV) with a valine at the
99 predicted catalytic position ([Fig. 1A](#)). The two HisKA_3 proteins have the DxxxQ/H motif with
100 the predicted glutamine or histidine catalytic residue ([Fig. 1A](#)). The 14 HKs encoding genes are
101 organized in operon with their cognate response regulator (RR) belonging to the OmpR (with
102 His_KA) or LuxR (with His_KA3) family, but one system is not functional (HK10655-
103 RR10650^{fs}) due to a pseudogenization of the RR in the CC-17 hypervirulent GBS lineage
104 ([Supplementary Table 1](#)).

105 We generated 14 strains, called the HK⁺ collection, with an alanine substitution of the
106 predicted phosphatase catalytic residue ([Fig. 1A](#)). Whole-genome sequencing confirmed the
107 chromosomal substitution of targeted base pairs and absence of secondary mutations in 11 out
108 of the 14 HK⁺ strains. In the three remaining HK⁺ (CovS_{T282A}, VikS_{T221A}, and RelS_{T208A}), we
109 sequenced independent mutants and selected one with a single secondary mutation
110 ([Supplementary Table 2](#)). Noteworthy, the selected VikS_{T221A} mutant has a non-synonymous

111 polymorphism in the glutamine transporter GlnPQ that we cannot exclude as a compensatory
112 mutation. Four independent *VikS_{T221A}* mutants also have putative compensatory mutations
113 ([Supplementary Table S2](#)), as frequently observed in mutants in the homologous *WalRK*
114 system essential for cell wall remodelling during growth and division⁴¹⁻⁴³.

115 Individual growth curves show a significant effect ($|F| > 0.1$, Mann Whitney test $p <$
116 10^{-4}) of the HK^+ mutation for four mutants, two gaining a reproductible fitness advantage
117 (*CovS_{T282A}* and *CiaH_{T228A}*) and two having specific phenotypes ([Fig. 1B](#)). Not surprisingly, the
118 slow growing *VikS_{T221A}* mutant is unstable and gives rise to faster-growing cultures likely due
119 to additional mutations ([Supplementary Fig. S1](#)). In contrast, the *SaeS_{T133A}* mutant exhibits a
120 density-dependent phenotype characterised by a decreasing growth rate in the exponential
121 phase and a lower final OD ([Supplementary Fig. S1](#)). Additionally, two mutants have increased
122 antibiotic susceptibilities: the *VikS_{T221A}* mutant against beta-lactams, in agreement with a
123 conserved function in cell wall metabolism, and the *RelS* mutant against fosfomycin
124 ([Supplementary Table S3](#)).

125 **HK^+ activate positive feedback loops.**

126 To test TCS activation, we first relied on positive feedback loops. This autoregulation
127 is often observed through direct transcriptional activation of the TCS operon by the activated
128 RR². We therefore analysed the transcription of all HKs and RRs encoding genes ($n = 41$,
129 including non-His_KA and His_KA3 TCSs and an orphan RR) in each HK^+ mutants by RNA-
130 sequencing from cultures grown in a standardized condition (THY, 37°C, $\text{OD}_{600} = 0.5$). A
131 positive feedback loop, defined by a $\text{FC} > 2$ and $\text{p-adj} < 10^{-4}$ for the HK and RR genes, is
132 observed in seven HK^+ mutants ([Fig. 1C](#)). Furthermore, two TCSs are significantly regulated
133 in an unrelated HK^+ mutant: the *HK11050-RR11055* system, which does not contain a His_KA
134 and His_KA3 domain, in the *VikS_{T221A}* mutant and the *RelRS* system, which is not positively
135 auto-regulated, in the *CiaH_{T228A}* mutant ([Fig. 1C](#)). As an independent approach to test TCS

136 activation, we introduced in each mutant a vector expressing an epitope-tagged copy of the
137 cognate regulator. For two mutants (VikS_{T221A} and RelS_{T208A}), an increased level of
138 phosphorylation of the ectopically expressed regulator is detected in the HK⁺ mutant compared
139 to the WT strain after Phos-Tag electrophoresis and western analysis with anti-FLAG
140 antibodies (Fig. 1D). Overall, by considering epitope-tagged RR activation by phosphorylation
141 and positive feedback loops, the majority (8/14) of HK⁺ mutations appear to activate the
142 corresponding TCS signaling pathway.

143 **The activated gene regulatory network.**

144 To characterise the activated pathways, we analysed the RNA-seq profiles of each HK⁺
145 mutant grown under standardised conditions, independent of specific environmental cues (*i.e.*,
146 exponential phase in rich media at 37°C). As illustrated with HK11030_{T245A} and VncS_{T245A}
147 (Fig. 2A), six HK⁺ mutants (including SaeS_{T133A}, BceS_{V124A}, HK02290_{H188A}, and DltS_{T184A}) are
148 associated with highly significant activation of specific genes (p-adj < 10⁻²⁵⁰) (Supplementary
149 Fig. S2). Four additional mutants (RelS_{T208A}, CiaH_{T228A}, VikS_{T221A}, and CovS_{T282A}) are
150 associated with an intermediate activation of larger gene sets (p-adj > 10⁻¹⁵⁰), while the
151 remaining four (HssS_{T150A}, LiaS_{Q149A}, PhoS_{T345A}, and the HK10655_{T267A} with a frameshifted
152 RR) gave no or low significant signals (p-adj > 10⁻¹⁰) (Supplementary Fig. S2).

153 Since most RRs are transcriptional activators, we focused the analysis on activated
154 genes. By applying strict thresholds (FC > 3, p-adj < 10⁻⁴) for normalisation between samples
155 and excluding genes with very low read counts in all samples and genes localised in mobile
156 genetic elements, 219 genes (11.9% of the 1838 genes analysed) are transcriptionally activated
157 in at least one HK⁺ mutant (Supplementary Table S4E). Transcriptional activation can be up to
158 8000-fold, with an average fold change of 61.6-fold and an uneven distribution between HK⁺
159 mutants (Fig. 2B).

160 The number of activated genes ranges from 3 (HK11030_{T245A}) to 139 (VikS_{T221A}) (Fig.
161 [2B](#) and [Supplementary Table S4](#)). Five regulatory systems activate a specific genetic program,
162 four of them (HK11030_{T245A}, HK02290_{H188A}, VncS_{T245A}, DltS_{T184A}) positively regulating a
163 single functional genetic module composed of their own operon and at least one additional gene
164 involved in the cellular response localized into, or adjacent to, the TCS operon (Fig. [2C](#)), and
165 one system (CiaH_{T228A}) coordinating the activation of at least six independent loci
166 ([Supplementary Fig. S3](#)). Four additional TCSs activate specific genes but share 1 to 3 activated
167 genes with the VikS_{T221A} mutant ([Fig. 2D](#)). One of these connected systems (HssS_{T150A}) is
168 specialised in haem detoxification via the transcriptional activation of the *hrtBA* genes encoding
169 a specific ABC transporter⁴⁴, which is similarly activated in the VikS_{T221A} mutant. The three
170 additional connected systems activate several loci involved in host-pathogen interaction
171 (SaeS_{T133A}: adhesins and secreted proteins), drug resistance (BceS_{V124A}: transporters and
172 peptidase), or nucleotide metabolism (RelS_{T208A}: *de novo* purine synthesis and
173 ectonucleotidases), with (SaeS_{T133A}, BceS_{V124A}) or without (RelS_{T208A}) a positive feedback loop
174 ([Fig. 2D](#) and [Supplementary Fig. S3](#)).

175 **Positive and negative interaction between TCS systems.**

176 Overall, the HK⁺ mutation activates the signaling pathway for 10 out of 12 TCSs ([Fig.](#)
177 [2E](#)), excluding the CovS_{T282A} repressing system analysed separately and the negative control
178 HK10655_{T267A} with a frameshifted RR. Notably, each HK⁺ mutant is associated with the
179 activation of specific genes, except the global regulator VikRS ([Fig. 2E](#) and [Supplementary](#)
180 [Table S4E](#)). As expected, the VikS_{T221A} regulon included several operons involved in cell wall
181 metabolism ([Supplementary Fig S3](#)). However, constitutive activation of VikS probably leads
182 to the activation of related stress and cell-wall signaling pathways. To identify relationships
183 between TCS pathways involved in related processes, we analysed the 219 genes activated in
184 at least one HK⁺ mutant for their expression in the whole RNA-seq dataset. This analysis

185 confirmed the partial activation of SaeRS signaling in the *VikS_{T221A}* mutant (a shared CovR
186 connection in fact, see specific section below) sustained by genes with $1 < FC < 3$ and significant
187 but higher p-adj value compared to the *SaeS_{T133A}* activated system ([Supplementary Table S4](#)).
188 Similarly, by considering significantly regulated genes with lower thresholds ($1 < IFCI < 3$, p-
189 adj < 0.05), significant positive or antagonistic interactions were detected between signaling
190 pathways (e.g., *DltS* activating *CiaH* and *VikS*, *CiaH* antagonising *RelS*, *HK02290*
191 antagonising *HK11030*). Finally, relaxing the thresholds also reveals the first five genes of the
192 *phoRS* operon as the most and only significantly up-regulated genes ($1.5 < FC < 1.75$; $7.10^{-3} < p-$
193 adj $< 10^{-5}$) in the *PhoS_{T345A}* mutant ([Supplementary Table S4D](#)), suggesting a conserved
194 mechanism of phosphatase activity but an inefficient activation of the *PhoR* regulator in the
195 corresponding HK^+ mutant.

196 **Activation of the global repressor of virulence CovRS.**

197 The CovRS system plays a critical role in regulating GBS virulence by acting as a global
198 repressor⁴⁵. Analysis of RNA-seq to identify negative regulation using similar thresholds ($-$
199 $3 > FC$, p-adj $< 10^{-4}$) revealed the repression of 32 genes, primarily in *VikS_{T221A}* (17 genes) and
200 *CovS_{T282A}* (14 genes) mutants ([Supplementary Table S4](#)). Notably, the most highly repressed
201 gene (22-fold by *VikRS*) encodes a D-L endopeptidase, reminiscent of *WalRK* homologous
202 systems⁴¹. However, only 5 of the repressed genes in the *CovS_{T282A}* mutant belong to the CovR
203 regulon previously characterized with inactivated mutants and genome-wide binding
204 experiments⁴⁵. Comparative analysis between *CovS_{T282A}* (activated) and *CovR_{D53A}*
205 (inactivated) transcriptomes shows the activation of CovRS signaling when the CovR repressor
206 is inactive without significant over-repression in the HK^+ mutant ([Fig. 3A](#)). Nevertheless, a
207 significant inverse correlation between the *CovS_{T282A}* and *CovR_{D53A}* transcriptomes is observed
208 for genes that do not belong to the direct CovR regulon ([Fig. 3B](#)), suggesting that overactivation

209 of CovR primarily increases binding to co-regulated promoters and low-affinity binding sites,
210 and in agreement with CovR being already significantly phosphorylated in the WT strain ⁴⁵.

211 The CovS_{T282A} mutation offers insight into the complexity of the CovR regulatory
212 network but is less informative than the inactivation of the system (Fig. 3A). We therefore
213 included the CovR_{D53A} transcriptome in the HK⁺ dataset. The global gene network reveals
214 connections between CovR-repressed genes and SaeS_{T133A}, VikS_{T221A}, or BceS_{V124A} activated-
215 genes (Fig. 2D). Notably, SaeS_{T133A} is highly connected with the direct CovR-repressed genes,
216 while BceS_{V124A} activates only three CovR indirectly regulated genes. Functional assays using
217 pigmented beta-haemoly sin/cytolysin (β -h/c) production as a natural reporter of CovR activity
218 first confirmed the non-pigmented and non-haemolytic phenotypes of the CovS_{T282A} mutant
219 (Fig. 3C), in agreement with CovR directly repressing the *cyl* operon encoding the β -h/c
220 synthesis and export machineries ⁴⁵⁻⁴⁷. The phenotype of six additional HK⁺ mutants are
221 different from the WT strain on selective media, either increasing (SaeS_{T133A}, VikS_{T221A}, and
222 RelS_{T208A}) or decreasing (BceS_{V124A}, CiaH_{T228A}, and LiaS_{Q149A}) pigmentation and/or haemolytic
223 activity (Fig. 3C). However, the lack of correlation between the transcription of the *cyl* operon
224 and the pigmentation/haemolytic phenotypes in several HK⁺ mutants (Fig. 3C) suggests
225 additional post-transcriptional regulatory mechanisms influencing β -h/c activity, particularly in
226 mutants with altered cell surface composition in which the toxin interacts ⁴⁸.

227 **The PbsP adhesin connects SaeRS and CovRS signaling.**

228 We sought to decipher the connection between the CovRS and SaeRS systems, two main
229 regulators of host-pathogen interactions. Published transcriptomes with *saeRS* deletion mutants
230 define a large regulon of 400-600 genes depending on growth conditions ⁴⁹. In contrast, analysis
231 of the SaeS_{T133A} transcriptome reveals the highly significant ($63 < \text{FC} < 8080$ -fold, $p\text{-adj} < 10^{-250}$)
232 activation of four genes only, along with a partial activation of the CovR regulon (Fig. 4A).
233 We confirmed the stratification of the SaeS_{T133A} differentially regulated genes by RT-qPCR,

234 validating 3 groups: the *pbsP* and *bvaP* genes, the *saeRS* operon, and the CovR-regulated genes
235 represented by the directly repressed genes *cylE* and *hvgA* (Fig. 4B).

236 Intrigued by the almost 50-fold difference between *pbsP* and *saeRS* up-regulation, we
237 analysed the genomic locus in detail. The 112 bp *pbsP-saeRS* intergenic region contains a P_{saeR}
238 promoter but no canonical transcriptional terminator. The integration of such a terminator
239 precisely after the *pbsP* stop codon in the *SaeS_{T133A}* mutant abolishes *saeRS* overexpression
240 while having no impact on other activated genes (Fig. 4B). Quantification of promoter activities
241 using β -galactosidase reporters confirms a similar activity of P_{saeR} in the WT and in *SaeS_{T133A}*
242 mutant, and the strong activation of P_{pbsP} upon activation of the *SaeRS* system (Fig. 4C). This
243 shows an indirect positive feedback loop of the *saeRS* operon, which is transcribed by its
244 constitutive promoter and regulated by *pbsP* termination readthrough. Interestingly, the basal
245 level of *saeRS* transcription in *SaeS_{T133A}* with the *pbsP* terminator is sufficient to fully activate
246 *pbsP* and *bvaP* (Fig. 4B), implying that the indirect feedback loop may be physiologically
247 relevant only to control the dynamic, and not the amplitude, of the response.

248 We next analysed the connection between *SaeRS* and *CovRS* signaling. The activation
249 of CovR-regulated genes in the *SaeS_{T133A}* mutant is intermediate when compared to the
250 *CovR_{D53A}* mutant (Fig. 3A and Fig. 4A). One hypothesis could be a competitive binding
251 between *SaeR* and *CovR*, but it is unlikely that all binding sites will allow both *SaeR*-activation
252 and *CovR*-repression. As an alternative, we hypothesized that the two genes specifically
253 regulated in the *SaeS_{T133A}* mutant, encoding the *PbsP* cell-wall anchored adhesin^{50,51} and the
254 *BvaP* secreted protein⁵², could be involved in the activation of the *CovR* regulon. Indeed,
255 deletion of *pbsP*, but not of *bvaP*, in the *SaeS_{T133A}* mutant restores a WT haemolytic activity
256 (Fig. 4D). In agreement with the phenotypes, the deletion of *pbsP* in the *SaeS_{T133A}* mutant
257 restores a WT level of the CovR-regulated genes *cylE* and *hvgA*, while the *saeRS* and *bvaP*
258 genes are still similarly up-regulated (Fig. 4E).

259 After cleavage by the enzyme sortase A and anchoring to the cell wall, the remaining
260 carboxy-terminal domain of an LPxTG adhesin can acts as a signaling molecule by interacting
261 with the transmembrane domain of a specific HK⁵³. We therefore considered this C-peptide
262 mechanism and constructed mutants expressing truncated PbsP variants in the SaeS_{T133A}
263 mutant. In-frame deletion of the PbsP C-peptide (e.g., 108 bp deletion including the LPxTG
264 cell-wall anchoring motif until the penultimate codon) has no effect on the induction of the
265 CovR-regulated haemolytic activity (Fig. 4D). In contrast, in-frame deletion of the PbsP
266 adhesin domain (1239 bp deletion leaving the signal peptide and the LPxTG cell wall anchoring
267 motif intact) restores the haemolytic activity of the SaeS_{T133A} mutant to WT level (Fig. 4D).
268 Furthermore, the growth defect of the SaeS_{T133A} mutant, which is similar to the growth defect
269 of the CovR_{D53A} mutant, is suppressed by deletion of *pbsP* or of the adhesin part of *pbsP*
270 (Supplementary Fig. S4). Thus, the PbsP adhesin domain triggers CovR signaling either by
271 interacting with CovS or co-regulatory proteins⁴⁷ or by inducing surface perturbations
272 specifically sensed by the CovRS system (Fig. 4F).

273 **Drug-independent activity of the BceRS three-component system.**

274 We next sought to decipher the function of the BceRS system which belongs to a
275 conserved TCS family that relies on a transporter to sense and transmit environmental signals
276 to the HK⁵⁴. Transcriptome of the BceS_{V124A} mutant reveals a 9-gene regulon, including the
277 *bceRS* operon and adjacent genes (Fig. 5A and Supplementary Fig. S2 and S3). Further
278 validation by RT-qPCR confirmed the 10 to 1000-fold activation of the regulon in absence of
279 drugs in the BceS_{V124A} mutant (Fig. 5B). As expected, mutation of the BceR regulator to a non-
280 phosphorylated form (BceR_{D55A}) abolishes the activation of the signaling pathway in the
281 BceS_{V124A} mutant (Fig. 5B). Interestingly, deletion of the transporter/sensor ($\Delta bceAB$) in the
282 BceS_{V124A} mutant also switches off the signaling pathway (Fig. 5B), showing the essential role
283 of the BceAB transporter in activating BceRS signaling in absence of inducing signals.

284 Typically, this TCS family confers resistance to antimicrobials targeting lipid II cell
285 wall metabolites such as nisin or bacitracin. Genetic activation of the pathway renders the
286 *BceS_{V124A}* mutant insensitive to nisin, which has a marked effect on the lag phase but not on
287 the growth rate of the WT strain, and increases resistance to gramicidin and, to a lesser extent,
288 bacitracin (Fig. 5C and Supplementary Fig. S5). Interestingly, the *BceS_{V124A}* mutant is also
289 more susceptible to antimicrobial peptides (colistin and polymyxin D) compared to the WT
290 strain, while equally susceptible as the WT to vancomycin (Fig. 5C and Supplementary Fig.
291 S5). Inactivation of the pathway in the *BceS_{V124A}* background by additional *BceR_{D55A}* or
292 $\Delta bceAB$ mutations leads to nisin hyper-susceptibility while restoring WT level of colistin
293 susceptibility (Fig. 5D). Nisin hyper-susceptibility is also observed for the single *BceR_{D55A}*
294 mutant (Fig. 5D), a phenotype not linked to down expression of BceRS regulated genes (Fig.
295 5B).

296 To test the current model of nisin resistance based on drug efflux and cleavage, we
297 inactivated the *BceCDE* transporter, the *BceO* substrate-binding protein, and the *BceP*
298 extracellular protease (Fig. 5A). Deletion of $\Delta bceD$ and $\Delta bceO$ in the WT or *BceS_{V124A}*
299 backgrounds has no impact on the nisin phenotypes of the respective parental strains (Fig. 5E),
300 excluding a major function in drug export or binding. In contrast, the $\Delta bceP$ mutant is slightly
301 more susceptible to nisin compared to the WT parental strain (Fig. 5E). However, deletion of
302 *bceP* in the *BceS_{V124A}* background was always associated with secondary mutations
303 inactivating the whole signaling pathway, this in five independent mutants (Supplementary
304 Table S2). This suggests that the *BceP* extracellular S41 protease⁵⁵ has a buffering role when
305 the pathway is activated, rather than directly cleaving drugs through an atypical mechanism, as
306 previously suggested⁵⁶.

307 To test if BceRS regulates an adaptive response rather than a resistance mechanism per
308 se, we pre-incubated the WT strain with nisin for four hours. Prior exposure to the drug

309 decreases the lag-phase in a dose-dependent manner upon subsequent exposure to higher nisin
310 concentrations (Fig. 5F). For instance, adaptation with 8 µg/ml nisin, a WT sub-inhibitory
311 concentration, confers a BceS_{V124A}-like resistance against a subsequent 64 µg/ml nisin
312 challenge (Fig. 5F). More generally, prior adaptation with a given nisin concentration increases
313 by a 4-fold factor the inhibiting concentration.

314 To summarize, the BceRS system is active in the absence of drug, required the BceAB
315 transporter, and the basal level of constitutive activity is necessary and sufficient to cope with
316 the stresses caused by sub-inhibitory nisin concentrations. The BceRS response is adaptative,
317 inducible as required, and confers protection against structurally unrelated drugs targeting lipid
318 II intermediates. However, individual regulated genes do not provide drug resistance and the
319 response is constrained by its cost against antimicrobial peptides. Overall, this suggests that the
320 BceRS system actively monitors and adjust surface-exposed lipid II metabolites, rather than
321 directly detoxifying drugs or drug-lipid II complexes. In line with a drug-independent
322 physiological function, the hypo-pigmented/haemolytic phenotypes of the BceS_{V124A} mutant
323 (Fig. 3C), independent of CovRS regulation of the *cyl* operon (Fig. 5B), suggest cell surface
324 alterations that could hinder interactions between the polyene backbone of the β-h/c toxin and
325 membranes^{46,48,57}.

326

327 **DISCUSSION**

328 This study establishes the HK⁺ approach as a method of choice for characterising TCS
329 signaling, both for mapping regulatory networks and for individual systems. This study was
330 made possible by the conserved mechanism of HK phosphatase activity originally proposed
331^{31,32}, which allowed a single residue to be targeted to activate the corresponding signaling
332 pathway. By systematically testing all HisKA and HisKA_3 systems in a bacterium, we show
333 the broad potential of this approach to reveal specialised, connected, and global regulatory

334 systems covering the functional diversity that has evolved from a simple two-component
335 architecture.

336 Targeting the HK phosphatase catalytic residue has the advantage of leaving a quasi-
337 native system. The gain-of-function is solely dependent on the HK mutation, with no change to
338 the RR and preservation of the physiological feedback loops. A second major advantage is that
339 it bypasses the need for environmental signals, which are often unknown or confounding when
340 having wide effect on bacterial physiology. In this respect, the SaeRS system is a remarkable
341 example. Previous studies demonstrated SaeR regulation of *pbsP* and *bvaP* during vaginal
342 colonization, among transcriptomic perturbations affecting nearly 40% of the genome ⁴⁹.
343 However, the regulon remained elusive due to lack of activation *in vitro* ⁴⁹. The HK⁺ approach
344 resolves the signaling pathway by revealing a specialized, and CovR-connected, pathway.
345 Comparison with the well characterized *Staphylococcus aureus* homologous system ⁵⁸
346 highlights the evolutionary divergence between regulatory circuits, particularly for those
347 regulating host-pathogen interactions which need to be studied in each species.

348 An originality is the mechanism linking the SaeRS and CovRS systems. Complex
349 regulatory wiring can be selected to mount co-ordinated responses, primary through
350 transcriptional cascades (a TCS regulating transcription of a second TCS) or connectors
351 (usually a TCS-regulated transmembrane protein modulating the activity of a second TCS) ⁵⁹.
352 The C-peptide of adhesins can act as connectors when the transmembrane end remaining after
353 cleavage of the LPxTG motif by sortase A interacts with a histidine kinase ⁵³. The mechanism
354 differs in GBS in which the PbsP adhesin domain acts as an extracellular signaling molecule to
355 activate CovR signaling, independently of cell wall anchoring. We hypothesize that the lysin-
356 rich and positively charged PbsP adhesin interacts with CovS, with the co-regulatory proteins
357 Abx1 and Stk1 ^{47,60}, or with the negatively charged membrane, recalling the activation of the
358 homologous CovRS system in *Streptococcus pyogenes* by cationic peptides ⁶¹. To complete the

359 regulatory circuit, CovR has previously been shown to repress *pbsP* in a strain-specific manner
360 ^{45,50,51}. The intertwining of SaeR and CovR signaling through PbsP constitutes an adaptive
361 mechanism for balancing adhesion and invasion and could contribute to the phenotypic and
362 pathogenicity variabilities observed within the species.

363 HK^+ mutations resolve TCS regulatory networks but reveal discrepancies in the
364 activation of signaling pathways. While primary sequence analysis of TCSs did not uncover
365 specific motifs correlating with high, intermediate, or low pathway activation, two underlying
366 factors may dampen the effect of HK^+ mutations. First, HK kinase activity can be inhibited by
367 interacting proteins, such as the small LiaF protein inhibiting LiaS ^{62,63} and the Pst/PhoU
368 proteins inhibiting PhoRS ^{64,65}. Genes encoding co-regulatory proteins are often themselves
369 regulated by the TCS, creating feedback loops that lock HKs in kinase-deficient conformation
370 and thus obliterate the effect of HK^+ mutations. Second, intermediary activation of the RelRS
371 and CiaRH pathways suggests buffering mechanisms for TCSs regulating multiple independent
372 loci and integrated cellular response. However, detailed analysis is required to decipher
373 phosphorylation dynamics in each phosphatase-deficient HK^+ and correlate *in vivo* RR
374 phosphorylation with regulatory network activation, considering variable factors like the source
375 of RR phosphorylation (kinase activity of the HK^+ variant, cross-talk by other HK, small
376 metabolites) and specific spontaneous dephosphorylation rates ^{27,66,67}.

377 The systematic approach validates the conservation of the dephosphorylation
378 mechanism. It also uncovers an unanticipated activation of the BceRS system with a degenerate
379 QMKV motif. Recent structural insights from *Bacillus subtilis* complexes into the membrane
380 environment supports a highly dynamic model of interactions between the BceAB transporter
381 and the BceS kinase- and phosphatase-competent conformations ^{68,69}. Our results with the HK^+
382 BceS indeed suggest that BceAB is necessary to stabilize the kinase-competent conformation
383 of BceS. Alternatively, BceAB could also provide the catalytic residue on the models suggested

384 for the auxiliary phosphatases RapH and SpoOE^{31,70}. At the phenotypic level, our results point
385 towards a need-based mechanism of target protection, as recently suggested for Bce-like system
386⁷¹⁻⁷³, and not towards a drug cleavage-exclusion mechanism as initially suggested^{74,75}. The
387 target protection mechanism relies on the binding of lipid II intermediates on a binding pocket
388 of BceAB⁶⁸. However, it is still unclear how the system releases lipid II when it is complexed
389 with drugs. Our results suggest an alternative scenario in which BceAB constantly monitor free
390 lipid II intermediate to minimize target exposure^{76,77}. This alternative is supported by the
391 steady-state activity of the BceRS pathway in the absence of drugs and is compatible with a
392 need-based mechanism. Further studies should test the entire BceRS pathway without relying
393 on a lipid II-drug detoxification mechanism, but rather on a mechanism that maintain the
394 steady-state level of free lipid II in presence of drugs.

395 To conclude, genetic activation by HK⁺ is a powerful approach to characterize positive
396 regulation by TCS. It circumvents the major drawback of studying systems that are usually non
397 activated in standard condition. Previous studies on individual TCSs have demonstrated the
398 potential of the approach, but it was unfortunately not widely adopted to date. Our systematic
399 analysis based on the conserved mechanism of phosphatase activity provides a blueprint to
400 decipher signaling, response dynamic, evolution of gene regulation, and regulatory networks.
401 The HK⁺ approach is recommended for the study of TCS in any species, either as a complement
402 or as a first choice alongside classical deletion mutants.

403

404 MATERIAL AND METHOD

405 Strain, mutants and genome sequencing.

406 The BM110 strain is a clinical isolate representative of the hypervirulent CC-17 clonal complex
407 responsible of most neonatal meningitis⁷⁸. The 2.2 Mb annotated genome is available under
408 the NCBI RefSeq reference NZ_LT714196. The standard growth condition is in Todd-Hewitt

409 medium supplemented with 1% yeast extract and 50 mM Hepes pH7.4 (THY) incubated in
410 static condition at 37°C.

411 Oligonucleotides and construction of vectors for site-directed mutagenesis and deletion are
412 detailed in Supplementary Table S5 and S6, respectively. Splicing-by-overlap PCR with high-
413 fidelity polymerase (Thermo Scientific Phusion Plus) were done with complementary primers
414 containing the desired mutations. The final PCR products contain mutations (SNP or deletion)
415 flanked on either side by 500 bp of sequence homologous to the targeted loci. Cloning is done
416 by Gibson assembly in the pG1 thermosensitive shuttle vector, before transformation in *E. coli*
417 XL1-blue (Stratagene) with erythromycin selection (150 µg/ml) at 37°C. Inserts are validated
418 by Sanger sequencing (Eurofins Genomics).

419 Mutant construction in GBS were done by a three-steps process involving: 1) electroporation
420 and selection of GBS transformants at 30°C with 5 µg/ml erythromycin (permissive replication
421 of the vector); 2) chromosomal integration on THY at 37°C with 5 µg/ml erythromycin (non-
422 permissive replication temperature); 3) de-recombination by serial passage in THY at 30°C
423 without antibiotic follow by colonies picking on THY at 37°C. Erythromycin-susceptible
424 colonies having lost the vector were tested by discriminatory PCR (MyTaq HS - Bioline) with
425 specific oligonucleotides (Supplementary Table S5) to select mutant over WT genotypes.

426 Genomic DNA of at least two independent mutants for each construction were purified from 1
427 ml of culture following manufacturer instruction for Gram-positive bacteria (DNeasy Blood
428 and Tissue – Qiagen) and sequenced (Illumina sequencing at Core facility or Eurofins
429 Genomics). High quality reads in Fastq were mapped against the BM110 genomes (55-419 x
430 coverage, mean 181 x) and analysed with Geneious Prime (2019.2.3 - Biomatters Ltd). Results
431 of genome sequencing for all mutants used in this study are summarized in Supplementary
432 Table S2.

433 **RNA sequencing.**

434 RNA purification, sequencing and analysis were conducted essentially as described for the
435 characterization of the virulence regulator CovR ⁴⁵. The 14 HK⁺ mutants have been split into
436 two series of 8 strains (7 mutants and one WT strain) and RNA was purified using three
437 independent replicate that were grown on different days. Overnight cultures were used to
438 inoculate THY (1/50), and 10 ml of culture are harvested in exponential growth phase (OD₆₀₀
439 = 0.5) after incubation at 37°C. Bacterial pellets are washed with cold PBS containing RNA
440 stabilization reagents (RNAProtect, Qiagen) before flash freezing and storage at -80°C. Total
441 RNA are extracted after cell wall mechanical lysis with 0.1 µm beads (Precellys Evolution,
442 Bertin Technologies) in RNAPro reagent (MP Biomedicals), and purified by chloroform
443 extraction and ethanol precipitation.

444 Samples were treated to remove residual DNA (TURBO DNase, Ambion) before
445 fluorescent-based quantification (Qubit RNA HS, Invitrogen) and quality validation (Agilent
446 Bioanalyzer 2100). Depletion of rRNA (FastSelect Bacterial, Qiagen), libraries construction
447 and sequencing were done following manufacturer instructions (TruSeq Stranded mRNA,
448 NextSeq 500, Illumina). Single-end strand-specific 75 bp reads were cleaned (cutadapt v2.10)
449 and mapped on the BM110 genome (Bowtie v2.5.1, with default parameters). Gene counts
450 (featureCounts, v2.0.0, parameters: -t gene -g locus_tag -s 1) were analysed with R v4.0.5 and
451 the Bioconductor package DESeq2 v1.30.1 ⁷⁹. Normalization, dispersion, and statistical tests
452 for differential expression were performed with independent filtering. For each comparison,
453 raw p-values were adjusted using Benjamini and Hochberg multiple tests ⁸⁰ and adjusted p-
454 value lower than 0.005 were considered significant. Raw sequencing reads and statistical
455 analysis are publicly available (GEO accession number GSE261394).
456 In addition to HK⁺ RNA-sequencing, we have included an independent CovST282A
457 transcriptome that was done simultaneously with the CovRD53A transcriptome ⁴⁵, the latter being

458 already reported altogether with CovR ChIP-seq experiment (GEO accession number
459 GSE158049). Gene networks are represented with the open-source software Cytoscape ⁸¹.

460 **RT-qPCR and promoter activity.**

461 For validation, independent RNA purifications from biological triplicates were done using the
462 same protocol, except that the cultures were grown on the same day and only 1 ml was
463 harvested. Reverse transcription and quantitative PCR (iScript Reverse Transcription and
464 SsoAdvanced Universal SYBR Green, BioRad) were done using specific primers
465 (Supplementary Table S5). Fold changes are calculated for each target relative to the WT strain
466 whose RNA were purified in parallel.

467 For promoter activities, promoters were amplified and cloned in the pTCV-lac vector
468 containing a β -galactosidase reporter (Supplementary Tables S4 and S5) and introduced in
469 GBS. Reporter activity was quantified in microplate format by colorimetric assay with ONPG
470 as substrate and permeabilized overnight cultures ⁴⁷. Reaction kinetics at 28°C were followed
471 by OD at 420 nm every 5 min (Tecan Infinite). Linear slopes (OD/min) were used to infer
472 enzymatic activities and were normalized for the initial cell density (OD 600 nm) of each
473 replicate.

474 **Growth curves and antibiotic susceptibilities.**

475 Growth curves are done in a volume of 150 μ l of THY inoculated with diluted overnight
476 cultures (1/500) in 96-wells microplates and incubated at 37°C with automatic recording of OD
477 600 nm every 10 minutes and 1 minute agitation by cycle (TECAN Infinite). Doubling times
478 are determined by fitting non-linear regression with a Malthusian growth model (GraphPad
479 Prism 10) in exponential phase ($R^2 > 0.99$) for each replicate. Fitness is calculated by dividing
480 the individual doubling time against the mean WT doubling time. For antibiotic susceptibilities,
481 concentrated drugs (10 x) were added to an aliquot of the starting cultures and serial two-fold
482 dilution were done in starting culture without drugs before incubation in the microplate reader.

483 Minimal Inhibitory Concentration (MIC) is done following EUCAST guidelines in Muller-
484 Hinton Fastidious culture media (MH-F, Becton Dickinson) media using custom AST Sensititre
485 96 wells plates (ThermoScientific) and 18h of incubation at 37°C.

486 **β-haemolytic activity.**

487 Columbia agar supplemented with 5% horse blood and Granada medium (BioMerieux) were
488 used to visualize β-haemolytic activity and pigmentation, respectively. Serial 10x dilutions of
489 cultures were spotted on media and incubated in aerobic (Columbia) or anaerobic (Granada
490 with AnaeroGen, Oxoid) conditions at 37°C. To highlight halo of lysis around colonies, images
491 are converted to gray scale and processed (Photoshop, Adobe) to uniformly adjust contrast and
492 brightness. Haemolytic titers were determined by a semi-quantitative method ⁴⁷. Serial 2-fold
493 dilution of cultures initially adjusted to 10⁹ CFU/ml in PBS were added (V/V) to 1%
494 defibrinated horse blood (Oxoid) in PBS supplemented with 0.2% glucose. After 1 hour of
495 incubation at 37°C, cells were gently pelleted and hemoglobin in supernatants quantified by
496 optical absorbance at 420 nm. Haemolytic activity of each strain was defined as the minimum
497 dilution that lysed at least 50% of red blood cells. Haemolytic titers are the ratio between the
498 haemolytic activity of each replicate against the haemolytic activity of the WT strain.
499 Haemolytic titers are then normalized against the WT strain (normalized WT titer = 1).

500 **RR phosphorylation level.**

501 Genes encoding RR were amplified and cloned by Gibson assembly (Supplementary Tables S4
502 and S5) in a custom-made pEX-CterFLAG vector containing a synthetic cassette with a
503 translational initiation site, a flexible Gly-Ala linker, a 3xFLAG epitope, and a transcriptional
504 terminator. Cassettes with genes of interest cloned in frame with the linker were excised with
505 restriction enzymes and cloned into the anhydro-tetracycline (aTc) inducible expression vector
506 pTCV_P_{tetO} ⁴⁵. Expression vectors were introduced in the corresponding HK⁺ mutants by
507 electroporation with kanamycin selection. Total protein extracts were prepared from 45 ml of

508 cultures in exponential phase in presence of 100 ng/ml aTc (Sigma) by mechanical lysis of
509 bacterial pellet (Precellys Evolution) resuspend in cold TBS buffer with EDTA-free protease
510 inhibitors (cComplete, Roche). Following clearance by centrifugation, 15 µg of proteins were
511 deposit in 12.5 % Phos-Tag SDS polyacrylamide gels (SuperSep Phos-Tag, Wako Pure
512 Chemical Industries Ltd) in loading dye buffer without EDTA and without sample heating to
513 avoid dephosphorylation of the labile aspartate ⁸². Electrophoresis (2 hours, 100V, 30 mA) in
514 Tris-glycine buffer was performed on ice bath. Semi-dry transfer on nitrocellulose membrane
515 (15 minutes, 15 V, Mini-Protean, BioRad) was follow by blocking (TBS buffer with 0.05%
516 Tween20 and 5% BSA), and hybridization with rabbit polyclonal anti-FLAG antibodies
517 (1:1500, Sigma F7425) and finally with secondary antibodies coupled to infrared dyes
518 (1:15000, Li-Cor IRDye 800CW). After final washing in TBS buffer without Tween20,
519 fluorescent signals were acquired (Odyssey Imager, Li-Cor). Ratio of phosphorylated and non-
520 phosphorylated protein were analysed with ImageJ from three independent protein extracts.

521 **Data availability**

522 Raw sequencing reads and statistical analysis have been deposited in the Gene Expression
523 Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>) under GEO accession number GSE261394.

524 **Acknowledgements**

525 This study was supported by Agence Nationale de la Recherche (VirEvol - ANR-22-CE15-
526 0024), and the National Laboratory of Excellence program - Integrative Biology of Emerging
527 Infectious Diseases (LabEx IBEID, ANR-10-LABX-62-IBEID). CC and MVM are recipients
528 of National PhD grants from Ecole Doctorale BioSpc (ED562) - Université Paris Cité.


529 **Competing interests**

530 GT is an employee and CB is the founder and owner of Scylla Biotech Srl. The company did
531 not provide funding and had no role in the design, conduct, or publication of the study. All other
532 authors declare no competing interests.

533

534 **Figure 1: Mutation of HK phosphatase catalytic residue activates TCS signaling.**

535 **Figure 1**




536 **A.** Conserved motif of the HisKA and HisKA_3 histidine kinases with the phospho-acceptor
 537 histidine (blue) and the predicted residue specifically involved in the phosphatase activity (red).
 538 The phosphatase residue is substituted by an alanine in the HK⁺ mutants.
 539 **B.** Fitness of HK⁺ mutants. The violin plots represent the distribution of the relative doubling
 540 time ($F = D_x / D_{WT \text{ mean}}$) in exponentially growth phase in rich medium with the median (bar)
 541 and the interquartile range (dashes). Data are from biological replicate ($n = 16$ for the WT, $n =$
 542 8 for mutants) and significant differences are highlighted (*, $|F| > 0.1$, Mann Whitney test $p <$
 543 10^{-4}). The bimodal distribution due to the occurrence of faster-growing VikS_{T221A} suppressors
 544 is highlighted (#).
 545 **C.** Activation of transcriptional feedback loops in HK⁺ mutants. Fold changes (FC) for all genes
 546 encoding TCS ($n = 41$) in each HK⁺ mutant after RNA-seq analysis are shown as dots. The HK-
 547 RR gene pair in the corresponding HK⁺ mutant is highlighted in red (e.g., *saeRS* in SaeS_{T133A}).
 548 Cross-regulations, defined as significant differential expression of a TCS gene pair not
 549 corresponding to the HK⁺ mutation, are highlighted in blue (*hk11050-rr11055* in VikS_{T221A}
 550 and *relRS* in CiaH_{T228A}).
 551 **D.** Activation of the VikR and the RelR response regulators by phosphorylation in the
 552 corresponding HK⁺ mutants. Upper: representative Phos-Tag western-blots with anti-FLAG

553 antibodies allowing to separate phosphorylated and non-phosphorylated forms of the
554 ectopically expressed epitope-tagged RR. Bottom: quantification of the proportion of
555 phosphorylated regulator in the WT (black) and the cognate HK⁺ mutant (red). Bars represent
556 the mean with SD of biological replicate (n = 3).

557

558 **Figure 2: The activated gene regulatory networks.**

Figure 2



559

560 **A.** Volcano plot of significant differential gene expression in the HK11030_{T245A} (right panel)
 561 and VcnS_{T245A} (left panel) mutants. Transcriptomes by RNA-seq against the WT strain were
 562 done in exponential growth phase in rich media (THY). Red dots highlight significantly
 563 differentially regulated genes above the thresholds FC > 3 , p-adj $< 10^{-4}$. Volcano plots for the
 564 14 HK⁺ mutant are provided in the related Supplementary Figure S2.

565 **B.** Violin distribution of transcriptional fold change in the 14 HK⁺ mutants. Coloured dots
 566 represent significantly activated (red) and repressed (green) genes ($|FC| > 3$, p-adj $< 10^{-4}$),
 567 respectively.

568 **C.** Activated chromosomal loci in selected HK⁺ mutants. Fold changes are indicated below the
 569 activated genes (red arrows). Transcriptional start sites identified by genome wide TSS
 570 mapping are represented by vertical flags. NCBI gene ID bordering the loci are shown in a


571 shortened form (e.g.: 11015 = BQ8897_RS11015). Activated loci for each HK⁺ mutant are
572 provided in the related Supplementary Figure S3.

573 **D. Network of activated genes.** Histidine kinases (orange nodes) are connected to their activated
574 genes (light to dark blue nodes). Edge thickness and gene node colour are proportional to
575 statistical significance and fold change, respectively. Activated genes in the CovR_{D53A} mutant
576 (black node) are included to account for the specificity of CovR as a global repressor.

577

578 **Figure 3: Activation of the global repressor of virulence CovR**


579 **Figure 3**



580 **A.** Volcano plot of significant fold changes in the CovR-active ($\text{CovS}_{\text{T}282\text{A}}$) and CovR-inactive
 581 ($\text{CovR}_{\text{D}53\text{A}}$) mutants. Coloured dots highlight genes according to CovR-regulatory mechanisms
 582 as previously defined by genome-wide binding: direct repression (red), CovR-binding requiring
 583 additional regulators for activation (orange), atypical CovR-binding inside ORFs or positive
 584 regulation (green), silencing or anti-silencing of genes in mobile genetic elements (blue).
 585 **B.** Comparison of fold changes between CovR inactivation and activation according to
 586 regulatory mechanisms. Significant correlations are highlighted (**: rs non-parametric
 587 spearman correlation, p (one-tailed) $< 10^{-4}$).
 588 **C.** Pigmentation and haemolytic phenotypes of the HK⁺ mutants on selective media. Spots of
 589 diluted cultures are incubated on Granada (Gr) and Columbia horse blood (Bl) plates in
 590 anaerobiosis and aerobiosis, respectively. Haemolytic activity is visualized by the dark halo on
 591 the inverted black and white photographs. The BM110 parental strain (WT) was added on each
 592 plate as control. Note that the $\text{VikS}_{\text{T}221\text{A}}$ mutant does not grow on Granada media, the basis of
 593 this phenotype requiring further investigation. The mean RNA-seq fold change with SD of the
 594 12 genes *cyl* operon encoding the pigmented haemolysin β -h/c directly repressed by CovR are
 595 indicated (* p -adj < 0.005).

596 **Figure 4: Adhesin-dependent wiring of the SaeR and CovR regulatory networks.**

Figure 4



597

598 **A.** Volcano plot of significant fold changes in the *SaeS_{T133A}* mutant. Dot colours highlight the
599 stratification of activated genes between *pbsP* and *bvaP* (green), the *saeRS* operon (orange) and
600 the CovR-regulated genes (red).

601 **B.** Indirect positive feedback loop of the *saeRS* operon. The *pbsP* and *saeRS* genes are separated
602 by a 112 bp intergenic region containing a *saeR* transcriptional start site located 31 bp from the
603 *SaeR* start codon. Transcriptional activation of *pbsP* and *saeRS* is uncoupled by the integration
604 of a canonical promoter at the 3' end of *pbsP*. Fold change of selected genes are quantified by
605 RT-qPCR in the *SaeS_{T133A}* (black) and in the *SaeS_{T133A} + pbsP terminator* (orange) mutants.
606 Mean and SD are shown for biological replicate ($n = 3$).

607 **C.** Activities of the P_{pbsP} and P_{saeR} promoters in the WT and *SaeS_{T133A}* mutant. Bars represent
608 the activity of the ectopic β -galactosidase reporter system under the control of the tested
609 promoters in the WT and the *SaeS_{T133A}* mutant. Mean and SD are shown for biological duplicate
610 ($n = 2$).

611 **D.** Hyper-haemolytic activity of the *SaeS_{T133A}* mutant is dependent on the *PbsP* adhesin.
612 Qualitative and semi-quantitative haemolytic activity are tested on Columbia blood agar media

613 and with defibrinated horse blood, respectively. The $\Delta cylE$ and CovR_{D53A} mutants are included
614 as negative and positive controls, respectively. Haemolytic titres are normalized against the WT
615 strain. Independent experiments are shown by dots with mean and SD for the biological
616 replicate (n = 8).


617 **E.** Upregulation of the PbsP adhesin activates CovR-regulated genes. Transcriptional fold
618 change of selected genes by RT-qPCR in the SaeS_{T133A} $\Delta pbsP$ (red) and SaeS_{T133A} $\Delta bvaP$
619 (green) double mutants. Mean and SD are shown for biological replicate (n = 3).

620 **F.** Wiring diagram of the SaeRS signaling pathway. The *saeRS* operon (orange) is transcribed
621 at a basal level by a constitutive promoter. Upon TCS activation, the SaeR regulator activates
622 the transcription of genes encoding the PbsP and BvaP virulence factors (green), and indirectly
623 its own operon through a *pbsP* terminator readthrough. The over-expression of the PbsP adhesin
624 domain, but not the carboxy-terminal part containing the LPxTG anchoring motif and the
625 hydrophobic C-peptide, is necessary to trigger CovR-regulated virulence factor expression.

626

627 **Figure 5: The BceRS three-component system controls an adaptive response.**

Figure 5



628

629 **A.** Schematic of the BceRS signaling pathway. The RNA-seq fold change scale in the BceS_{V124A}
630 mutant is shown below the horizontal line. The BceAB transporter (yellow) is the third
631 component of the regulatory system, predicted to sense and transduce the signal to BceS.
632 Functions currently assigned to each component are indicated by question marks.

633 **B.** BceAB is necessary to activate BceRS signaling in the absence of drugs. Fold changes during
634 exponential growth in rich media were quantified by RT-qPCR in the activated HK⁺ mutant
635 (BceS_{V124A}), in mutants with a non-phosphorylatable variant of the cognate regulator in the WT
636 (BceR_{D55A}) or activated (BceS_{V124A} BceR_{D55A}) backgrounds, and in a BceAB transporter mutant
637 in the activated background (BceS_{V124A} Δ). Bars represent the mean and SD of biological
638 replicate (n = 3).

639 **C.** Growth curves of the WT and activated BceS_{V124A} mutant in presence of increasing
640 concentration of drugs. The curves represent the mean and SEM of biological replicates (n =
641 4).

642 **D.** Drug susceptibilities of double mutants abolishing BceRS activation in the BceS_{V124A}
643 mutant. The curves represent the mean and SEM of biological replicates (n = 3).


644 **E.** Drug susceptibilities of $\Delta bceP$, $\Delta bceD$, and $\Delta bceO$ mutants in the activated mutants (left
645 panel) and/or the WT strain (right panel). The curves represent the mean and SEM of biological
646 replicates (n = 3).

647 **F.** Growth curves of the WT strain pre-exposed to nisin. Early exponential growing WT strain
648 were exposed for 4 hours to nisin (Adapt 0 to 128 μ g/ml) in THY at 37°C. After washing and
649 OD₆₀₀ normalization, each culture is inoculated in fresh rich media (THY) and with increasing
650 concentration of nisin (Nisin 64, 128, and 256 μ g/ml). The curves represent the mean and SEM
651 of biological replicates (n = 2).

652

653 **Supplementary Figure S1: Growth phenotype of the HK⁺ collection.**

Supplementary Figure S1



654

655 **A.** Growth curves of the HK⁺ collection. Cultures were done in rich media (THY) at 37°C in
656 microplate starting from independent isolated colonies. Data represents the mean with SEM for
657 each mutant (n = 8).

658 **B.** Same data as in panel A in non-logarithmic scale highlighting the four mutants with
659 significant phenotype.


660 **C.** Individual growth curves of each replicate of the VikS_{T221A} mutants (n = 8).

661 **D.** Doubling time in exponential growth phase. Malthusian non-linear fitting ($r^2 > 0.99$)
662 between OD₆₀₀ 0.001 and 0.25 (panel A) were used to infer doubling time. Boxes represent the
663 inter-quartile distance with median (horizontal lines), and the whiskers highlight minimal and
664 maximal value (n = 8).

665

666 **Supplementary Figure S2: Significant differential gene expression in the HK⁺ collection**

Supplementary Figure S2



667

668 Volcano plot of significant differential gene expression by RNA-seq in exponential growth
669 phase at 37°C in rich media for each HK⁺ mutant against the WT strain. Coloured dots represent
670 significantly activated (red) and repressed (green) genes (|FC| > 3, p-adj < 10⁻⁴), respectively.

671

672 **Supplementary Figure S3: Activated chromosomal loci by HK⁺.**

673 Fold changes determined by RNA-seq are indicated below the activated genes (red arrows).


674 Transcriptional start sites identified by genome wide TSS mapping are represented by vertical

675 flags. NCBI genes ID bordering the loci are shown in a shortened form (e.g.: 11015 =

676 BQ8897_RS11015). Frameshifted genes in the WT are marked (^{fs}).


677

Supplementary Figure S3



679 **Supplementary Figure S4: The fitness defect in SaeS_{T133A} is caused by the adhesin PbsP.**

Supplementary Figure S4



680

681 **A.** Growth curves of the WT (black), SaeS_{T133A} activated mutant (red), and the double SaeS_{T133A}
682 Δ pbsP (orange) and SaeS_{T133A} Δ bvaP (salmon) mutants. Data represent the mean and SD of a
683 single experiment with pre-cultures inoculated with independent isolated colonies (n = 8).

684 **B.** Same experiment with SaeS_{T133A} PbsP Δ intern (green), SaeS_{T133A} PbsP Δ C-ter (blue), and
685 SaeS_{T133A} + pbsP term (cyan).


686 **C.** Same experiment with CovR_{D53A} (pink) and Δ cylE (grey).

687 **D.** Corresponding doubling time in exponential growth phase. Malthusian non-linear fitting (r^2
688 > 0.99) between OD₆₀₀ 0.02 and 0.4 were used to infer doubling time. Dots represent biological
689 replicate (n = 8) with mean and SD.

690

691 **Supplementary Figure S5: Drug susceptibilities of BceS_{V124A}.**

Supplementary Figure S5



692

693 Growth curves of the WT and activated $BceS_{V124A}$ mutant in presence of increasing
694 concentration of bacitracin, polymyxin B, or vancomycin. Curves are mean and SEM from
695 biological replicate ($n = 3$).

696 **SUPPLEMENTARY TABLES LEGENDS**

697

698 **Supplementary Table S1: TCS-encoding genes in the hypervirulent BM110 strain.**

699 **Supplementary Table S2: List of strains with sequenced genome.**

700 **Supplementary Table 3: Antibiotic susceptibility.**

701 **Supplementary Tables S4: Transcriptome analysis of the HK+ collection.**

702 S4A: All results - RNA-seq normalized count - Mean of biological triplicate.

703 S4B: All results - Statistical analysis.

704 S4C: Genes excluded from the analysis (rRNA, transposase, mobile genetic elements, no
705 expression).

706 S4D: Differentially expressed genes (DEG) - threshold p-adj < 0.05

707 S4E: Activated genes in the HK+ collection (FC > 3, p-adj < 0.0001)

708 S4F: Repressed genes in the HK+ collection (FC < -3, p-adj < 0.0001)

709 S4G: Activated regulon in the HK+ collection (-3 > FC > 3, p-adj < 0.0001)

710 **Supplementary Table S5: Oligonucleotides.**

711 **Supplementary Table S6: Vector and mutant construction.**

712 **REFERENCES**

713 1 Stock, A. M., Robinson, V. L. & Goudreau, P. N. Two-component signal transduction.
714 *Annu Rev Biochem* **69**, 183-215, doi:10.1146/annurev.biochem.69.1.183 (2000).

715 2 Groisman, E. A. Feedback Control of Two-Component Regulatory Systems. *Annu Rev*
716 *Microbiol* **70**, 103-124, doi:10.1146/annurev-micro-102215-095331 (2016).

717 3 Groisman, E. A., Duprey, A. & Choi, J. How the PhoP/PhoQ System Controls Virulence
718 and Mg(2+) Homeostasis: Lessons in Signal Transduction, Pathogenesis, Physiology,
719 and Evolution. *Microbiol Mol Biol Rev* **85**, e0017620, doi:10.1128/MMBR.00176-20
720 (2021).

721 4 Francis, V. I. & Porter, S. L. Multikinase Networks: Two-Component Signaling Networks
722 Integrating Multiple Stimuli. *Annu Rev Microbiol* **73**, 199-223, doi:10.1146/annurev-
723 micro-020518-115846 (2019).

724 5 Sastry, A. V. *et al.* The *Escherichia coli* transcriptome mostly consists of independently
725 regulated modules. *Nature communications* **10**, 5536, doi:10.1038/s41467-019-
726 13483-w (2019).

727 6 Xie, Y. *et al.* An atlas of bacterial two-component systems reveals function and
728 plasticity in signal transduction. *Cell reports* **41**, 111502,
729 doi:10.1016/j.celrep.2022.111502 (2022).

730 7 Capra, E. J. & Laub, M. T. Evolution of Two-Component Signal Transduction Systems.
731 *Annu Rev Microbiol*, doi:10.1146/annurev-micro-092611-150039 (2012).

732 8 Salazar, M. E. & Laub, M. T. Temporal and evolutionary dynamics of two-component
733 signaling pathways. *Curr Opin Microbiol* **24**, 7-14, doi:10.1016/j.mib.2014.12.003
734 (2015).

735 9 Perez, J. C. & Groisman, E. A. Evolution of transcriptional regulatory circuits in bacteria.
736 *Cell* **138**, 233-244, doi:10.1016/j.cell.2009.07.002 (2009).

737 10 Rapun-Araiz, B., Haag, A. F., Solano, C. & Lasa, I. The impact of two-component
738 sensorial network in staphylococcal speciation. *Curr Opin Microbiol* **55**, 40-47,
739 doi:10.1016/j.mib.2020.02.004 (2020).

740 11 Perez, J. C. & Groisman, E. A. Transcription factor function and promoter architecture
741 govern the evolution of bacterial regulons. *Proc Natl Acad Sci U S A* **106**, 4319-4324,
742 doi:10.1073/pnas.0810343106 (2009).

743 12 Choi, J. & Groisman, E. A. Horizontally acquired regulatory gene activates ancestral
744 regulatory system to promote *Salmonella* virulence. *Nucleic Acids Res* **48**, 10832-
745 10847, doi:10.1093/nar/gkaa813 (2020).

746 13 Ghose, D. A., Przydzial, K. E., Mahoney, E. M., Keating, A. E. & Laub, M. T. Marginal
747 specificity in protein interactions constrains evolution of a paralogous family. *Proc Natl*
748 *Acad Sci U S A* **120**, e2221163120, doi:10.1073/pnas.2221163120 (2023).

749 14 Rapun-Araiz, B. *et al.* Systematic Reconstruction of the Complete Two-Component
750 Sensorial Network in *Staphylococcus aureus*. *mSystems* **5**,
751 doi:10.1128/mSystems.00511-20 (2020).

752 15 Villanueva, M. *et al.* Sensory deprivation in *Staphylococcus aureus*. *Nature*
753 *communications* **9**, 523, doi:10.1038/s41467-018-02949-y (2018).

754 16 Galagan, J. E. *et al.* The *Mycobacterium tuberculosis* regulatory network and hypoxia.
755 *Nature* **499**, 178-183, doi:10.1038/nature12337 (2013).

756 17 Minch, K. J. *et al.* The DNA-binding network of *Mycobacterium tuberculosis*. *Nature*
757 *communications* **6**, 5829, doi:10.1038/ncomms6829 (2015).

758 18 Trouillon, J. *et al.* Determination of the two-component systems regulatory network
759 reveals core and accessory regulations across *Pseudomonas aeruginosa* lineages.
760 *Nucleic Acids Res*, doi:10.1093/nar/gkab928 (2021).

761 19 Gao, R. & Stock, A. M. Biological insights from structures of two-component proteins.
762 *Annu Rev Microbiol* **63**, 133-154, doi:10.1146/annurev.micro.091208.073214 (2009).

763 20 Jacob-Dubuisson, F., Mechaly, A., Betton, J. M. & Antoine, R. Structural insights into
764 the signalling mechanisms of two-component systems. *Nat Rev Microbiol* **16**, 585-593,
765 doi:10.1038/s41579-018-0055-7 (2018).

766 21 Buschiazza, A. & Trajtenberg, F. Two-Component Sensing and Regulation: How Do
767 Histidine Kinases Talk with Response Regulators at the Molecular Level? *Annu Rev
768 Microbiol* **73**, 507-528, doi:10.1146/annurev-micro-091018-054627 (2019).

769 22 Pioszak, A. A. & Ninfa, A. J. Genetic and biochemical analysis of phosphatase activity of
770 *Escherichia coli* NRII (NtrB) and its regulation by the PII signal transduction protein. *J
771 Bacteriol* **185**, 1299-1315, doi:10.1128/JB.185.4.1299-1315.2003 (2003).

772 23 Dutta, R., Yoshida, T. & Inouye, M. The critical role of the conserved Thr247 residue in
773 the functioning of the osmosensor EnvZ, a histidine Kinase/Phosphatase, in *Escherichia
774 coli*. *J Biol Chem* **275**, 38645-38653, doi:10.1074/jbc.M005872200 (2000).

775 24 Hsing, W., Russo, F. D., Bernd, K. K. & Silhavy, T. J. Mutations that alter the kinase and
776 phosphatase activities of the two-component sensor EnvZ. *J Bacteriol* **180**, 4538-4546,
777 doi:10.1128/JB.180.17.4538-4546.1998 (1998).

778 25 Kenney, L. J. How important is the phosphatase activity of sensor kinases? *Curr Opin
779 Microbiol* **13**, 168-176, doi:10.1016/j.mib.2010.01.013 (2010).

780 26 Laub, M. T. & Goulian, M. Specificity in two-component signal transduction pathways.
781 *Annu Rev Genet* **41**, 121-145, doi:10.1146/annurev.genet.41.042007.170548 (2007).

782 27 Gao, R. & Stock, A. M. Quantitative Kinetic Analyses of Shutting Off a Two-Component
783 System. *MBio* **8**, doi:10.1128/mBio.00412-17 (2017).

784 28 Trajtenberg, F. *et al.* Regulation of signaling directionality revealed by 3D snapshots of
785 a kinase:regulator complex in action. *eLife* **5**, doi:10.7554/eLife.21422 (2016).

786 29 Casino, P., Rubio, V. & Marina, A. Structural insight into partner specificity and
787 phosphoryl transfer in two-component signal transduction. *Cell* **139**, 325-336,
788 doi:10.1016/j.cell.2009.08.032 (2009).

789 30 Skerker, J. M. *et al.* Rewiring the specificity of two-component signal transduction
790 systems. *Cell* **133**, 1043-1054, doi:10.1016/j.cell.2008.04.040 (2008).

791 31 Huynh, T. N. & Stewart, V. Negative control in two-component signal transduction by
792 transmitter phosphatase activity. *Mol Microbiol* **82**, 275-286, doi:10.1111/j.1365-
793 2958.2011.07829.x (2011).

794 32 Huynh, T. N., Noriega, C. E. & Stewart, V. Conserved mechanism for sensor
795 phosphatase control of two-component signaling revealed in the nitrate sensor NarX.
796 *Proc Natl Acad Sci U S A* **107**, 21140-21145, doi:10.1073/pnas.1013081107 (2010).

797 33 Willett, J. W. & Kirby, J. R. Genetic and Biochemical Dissection of a HisKA Domain
798 Identifies Residues Required Exclusively for Kinase and Phosphatase Activities. *PLoS
799 Genet* **8**, e1003084, doi:10.1371/journal.pgen.1003084 (2012).

800 34 Mikkelsen, H., Hui, K., Barraud, N. & Filloux, A. The pathogenicity island encoded
801 PvrSR/RcsCB regulatory network controls biofilm formation and dispersal in
802 *Pseudomonas aeruginosa* PA14. *Mol Microbiol* **89**, 450-463, doi:10.1111/mmi.12287
803 (2013).

804 35 Horstmann, N. *et al.* Phosphatase activity of the control of virulence sensor kinase CovS
805 is critical for the pathogenesis of group A *Streptococcus*. *PLoS Pathog* **14**, e1007354,
806 doi:10.1371/journal.ppat.1007354 (2018).

807 36 Wayne, K. J., Li, S., Kazmierczak, K. M., Tsui, H. C. & Winkler, M. E. Involvement of WalK
808 (VicK) phosphatase activity in setting WalR (VicR) response regulator phosphorylation
809 level and limiting cross-talk in *Streptococcus pneumoniae* D39 cells. *Mol Microbiol* **86**,
810 645-660, doi:10.1111/mmi.12006 (2012).

811 37 Sharkey, L. K. R. *et al.* The two-component system WalkR provides an essential link
812 between cell wall homeostasis and DNA replication in *Staphylococcus aureus*. *mBio* **14**,
813 e0226223, doi:10.1128/mbio.02262-23 (2023).

814 38 Armistead, B., Oler, E., Adams Waldorf, K. & Rajagopal, L. The Double Life of Group B
815 *Streptococcus*: Asymptomatic Colonizer and Potent Pathogen. *J Mol Biol* **431**, 2914-
816 2931, doi:10.1016/j.jmb.2019.01.035 (2019).

817 39 Vornhagen, J., Adams Waldorf, K. M. & Rajagopal, L. Perinatal Group B Streptococcal
818 Infections: Virulence Factors, Immunity, and Prevention Strategies. *Trends Microbiol*,
819 doi:10.1016/j.tim.2017.05.013 (2017).

820 40 Thomas, L. & Cook, L. Two-Component Signal Transduction Systems in the Human
821 Pathogen *Streptococcus agalactiae*. *Infect Immun* **88**, doi:10.1128/IAI.00931-19
822 (2020).

823 41 Dobihal, G. S., Brunet, Y. R., Flores-Kim, J. & Rudner, D. Z. Homeostatic control of cell
824 wall hydrolysis by the WalRK two-component signaling pathway in *Bacillus subtilis*.
825 *Elife* **8**, doi:10.7554/elife.52088 (2019).

826 42 Monk, I. R., Howden, B. P., Seemann, T. & Stinear, T. P. Spontaneous secondary
827 mutations confound analysis of the essential two-component system WalkR in
828 *Staphylococcus aureus*. *Nature communications* **8**, 14403, doi:10.1038/ncomms14403
829 (2017).

830 43 Winkler, M. E. & Hoch, J. A. Essentiality, bypass, and targeting of the YycFG (VicRK)
831 two-component regulatory system in gram-positive bacteria. *J Bacteriol* **190**, 2645-
832 2648, doi:10.1128/JB.01682-07 (2008).

833 44 Joubert, L. *et al.* Visualization of the role of host heme on the virulence of the heme
834 auxotroph *Streptococcus agalactiae*. *Scientific reports* **7**, 40435,
835 doi:10.1038/srep40435 (2017).

836 45 Mazzuoli, M. V. *et al.* The CovR regulatory network drives the evolution of Group B
837 *Streptococcus* virulence. *PLoS Genet* **17**, e1009761, doi:10.1371/journal.pgen.1009761
838 (2021).

839 46 Whidbey, C. *et al.* A hemolytic pigment of Group B *Streptococcus* allows bacterial
840 penetration of human placenta. *J Exp Med* **210**, 1265-1281,
841 doi:10.1084/jem.20122753 (2013).

842 47 Firon, A. *et al.* The Abi-domain protein Abx1 interacts with the CovS histidine kinase to
843 control virulence gene expression in group B *Streptococcus*. *PLoS Pathog* **9**, e1003179,
844 doi:10.1371/journal.ppat.1003179 (2013).

845 48 Armistead, B. *et al.* Lipid analogs reveal features critical for hemolysis and diminish
846 granadaene mediated Group B *Streptococcus* infection. *Nature communications* **11**,
847 1502, doi:10.1038/s41467-020-15282-0 (2020).

848 49 Cook, L. C., Hu, H., Maienschein-Cline, M. & Federle, M. J. A vaginal tract signal
849 detected by the GBS SaeRS system elicits transcriptomic changes and enhances murine
850 colonization. *Infect Immun*, doi:10.1128/IAI.00762-17 (2018).

851 50 Buscetta, M. *et al.* PbsP, a cell wall-anchored protein that binds plasminogen to
852 promote hematogenous dissemination of group B *Streptococcus*. *Mol Microbiol* **101**,
853 27-41, doi:10.1111/mmi.13357 (2016).

854 51 Lentini, G. *et al.* The plasminogen binding protein PbsP is required for brain invasion
855 by hypervirulent CC17 Group B streptococci. *Scientific reports* **8**, 14322,
856 doi:10.1038/s41598-018-32774-8 (2018).

857 52 Thomas, L. S. & Cook, L. C. A Novel Conserved Protein in *Streptococcus agalactiae*,
858 BvAP, Is Important for Vaginal Colonization and Biofilm Formation. *mSphere*,
859 e0042122, doi:10.1128/msphere.00421-22 (2022).

860 53 Hall, J. W. *et al.* An intramembrane sensory circuit monitors sortase A-mediated
861 processing of streptococcal adhesins. *Science signaling* **12**,
862 doi:10.1126/scisignal.aas9941 (2019).

863 54 Mascher, T. Bacterial (intramembrane-sensing) histidine kinases: signal transfer rather
864 than stimulus perception. *Trends Microbiol* **22**, 559-565,
865 doi:10.1016/j.tim.2014.05.006 (2014).

866 55 Sommerfield, A. G. & Darwin, A. J. Bacterial Carboxyl-Terminal Processing Proteases
867 Play Critical Roles in the Cell Envelope and Beyond. *J Bacteriol* **204**, e0062821,
868 doi:10.1128/jb.00628-21 (2022).

869 56 Khosa, S. *et al.* Structural basis of lantibiotic recognition by the nisin resistance protein
870 from *Streptococcus agalactiae*. *Scientific reports* **6**, 18679, doi:10.1038/srep18679
871 (2016).

872 57 Armistead, B. *et al.* Hemolytic Membrane Vesicles of Group B *Streptococcus* Promote
873 Infection. *J Infect Dis* **223**, 1488-1496, doi:10.1093/infdis/jiaa548 (2021).

874 58 Jenul, C. & Horswill, A. R. Regulation of *Staphylococcus aureus* Virulence. *Microbiol
875 Spectr* **7**, doi:10.1128/microbiolspec.GPP3-0031-2018 (2019).

876 59 Mitrophanov, A. Y. & Groisman, E. A. Signal integration in bacterial two-component
877 regulatory systems. *Genes Dev* **22**, 2601-2611, doi:10.1101/gad.1700308 (2008).

878 60 Lin, W. J. *et al.* Threonine phosphorylation prevents promoter DNA binding of the
879 Group B *Streptococcus* response regulator CovR. *Mol Microbiol* **71**, 1477-1495,
880 doi:10.1111/j.1365-2958.2009.06616.x (2009).

881 61 Gryllos, I. *et al.* Induction of group A *Streptococcus* virulence by a human antimicrobial
882 peptide. *Proc Natl Acad Sci U S A* **105**, 16755-16760, doi:10.1073/pnas.0803815105
883 (2008).

884 62 Jani, S. *et al.* Low phosphatase activity of LiaS and strong LiaR-DNA affinity explain the
885 unusual LiaS to LiaR in vivo stoichiometry. *BMC Microbiol* **20**, 104, doi:10.1186/s12866-
886 020-01796-6 (2020).

887 63 Sanson, M. A. *et al.* The LiaFSR Transcriptome Reveals an Interconnected Regulatory
888 Network in Group A *Streptococcus*. *Infect Immun* **89**, e0021521,
889 doi:10.1128/IAI.00215-21 (2021).

890 64 Lamarche, M. G., Wanner, B. L., Crepin, S. & Harel, J. The phosphate regulon and
891 bacterial virulence: a regulatory network connecting phosphate homeostasis and
892 pathogenesis. *FEMS Microbiol Rev* **32**, 461-473, doi:10.1111/j.1574-
893 6976.2008.00101.x (2008).

894 65 Baek, S. & Lee, E. J. PhoU: a multifaceted regulator in microbial signaling and
895 homeostasis. *Curr Opin Microbiol* **77**, 102401, doi:10.1016/j.mib.2023.102401 (2024).

896 66 Gao, R. & Stock, A. M. Probing kinase and phosphatase activities of two-component
897 systems *in vivo* with concentration-dependent phosphorylation profiling. *Proc Natl
898 Acad Sci U S A* **110**, 672-677, doi:10.1073/pnas.1214587110 (2013).

899 67 Butcher, R. J. & Tabor, J. J. Real-time detection of response regulator phosphorylation
900 dynamics in live bacteria. *Proc Natl Acad Sci U S A* **119**, e2201204119,
901 doi:10.1073/pnas.2201204119 (2022).

902 68 George, N. L., Schilmiller, A. L. & Orlando, B. J. Conformational snapshots of the
903 bacitracin sensing and resistance transporter BceAB. *Proc Natl Acad Sci U S A* **119**,
904 e2123268119, doi:10.1073/pnas.2123268119 (2022).

905 69 George, N. L. & Orlando, B. J. Architecture of a complete Bce-type antimicrobial
906 peptide resistance module. *Nature communications* **14**, 3896, doi:10.1038/s41467-
907 023-39678-w (2023).

908 70 Parashar, V., Mirouze, N., Dubnau, D. A. & Neiditch, M. B. Structural basis of response
909 regulator dephosphorylation by Rap phosphatases. *PLoS Biol* **9**, e1000589,
910 doi:10.1371/journal.pbio.1000589 (2011).

911 71 Fritz, G. *et al.* A New Way of Sensing: Need-Based Activation of Antibiotic Resistance
912 by a Flux-Sensing Mechanism. *mBio* **6**, e00975, doi:10.1128/mBio.00975-15 (2015).

913 72 Kobras, C. M. *et al.* BceAB-Type Antibiotic Resistance Transporters Appear To Act by
914 Target Protection of Cell Wall Synthesis. *Antimicrob Agents Chemother* **64**,
915 doi:10.1128/AAC.02241-19 (2020).

916 73 Koh, A., Gibbon, M. J., Van der Kamp, M. W., Pudney, C. R. & Gebhard, S. Conformation
917 control of the histidine kinase BceS of *Bacillus subtilis* by its cognate ABC-transporter
918 facilitates need-based activation of antibiotic resistance. *Mol Microbiol* **115**, 157-174,
919 doi:10.1111/mmi.14607 (2021).

920 74 Reiners, J. *et al.* The N-terminal Region of Nisin Is Important for the BceAB-Type ABC
921 Transporter NsrFP from *Streptococcus agalactiae* COH1. *Frontiers in microbiology* **8**,
922 1643, doi:10.3389/fmicb.2017.01643 (2017).

923 75 Yang, Y. *et al.* Role of Two-Component System Response Regulator bceR in the
924 Antimicrobial Resistance, Virulence, Biofilm Formation, and Stress Response of Group
925 B *Streptococcus*. *Frontiers in microbiology* **10**, 10, doi:10.3389/fmicb.2019.00010
926 (2019).

927 76 Piepenbreier, H., Diehl, A. & Fritz, G. Minimal exposure of lipid II cycle intermediates
928 triggers cell wall antibiotic resistance. *Nature communications* **10**, 2733,
929 doi:10.1038/s41467-019-10673-4 (2019).

930 77 Kingston, A. W., Zhao, H., Cook, G. M. & Helmann, J. D. Accumulation of heptaprenyl
931 diphosphate sensitizes *Bacillus subtilis* to bacitracin: implications for the mechanism
932 of resistance mediated by the BceAB transporter. *Mol Microbiol* **93**, 37-49,
933 doi:10.1111/mmi.12637 (2014).

934 78 Da Cunha, V. *et al.* *Streptococcus agalactiae* clones infecting humans were selected
935 and fixed through the extensive use of tetracycline. *Nature communications* **5**, 4544,
936 doi:10.1038/ncomms5544 (2014).

937 79 Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
938 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550, doi:10.1186/s13059-
939 014-0550-8 (2014).

940 80 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and
941 Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society: Series
942 B* **57**, 289-300, doi:10.1111/j.2517-6161.1995.tb02031.x (1995).

943 81 Shannon, P. *et al.* Cytoscape: a software environment for integrated models of
944 biomolecular interaction networks. *Genome Res* **13**, 2498-2504,
945 doi:10.1101/gr.1239303 (2003).

946 82 Barbieri, C. M. & Stock, A. M. Universally applicable methods for monitoring response
947 regulator aspartate phosphorylation both *in vitro* and *in vivo* using Phos-tag-based
948 reagents. *Anal Biochem* **376**, 73-82, doi:10.1016/j.ab.2008.02.004 (2008).

949